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Background: The aim of the present study was to examine how liver markers are associated with insulin resistance
in Japanese community-dwelling adults.
Methods: This cross-sectional study included 587 men aged 58 ± 14 (mean ± standard deviation; range, 20–89)
years and 755 women aged 60 ± 12 (range, 21–88) years. The study sample consisted of 998 (74.4%) non-obese
[body mass index (BMI) <25.0 kg/m2] and 344 (25.6%) overweight (BMI ≥25 kg/m2) subjects. Insulin resistance was
defined by homeostasis model assessment of insulin resistance (HOMA-IR) of at least 2.5, and HOMA-IR and
potential confounders were compared between the groups. Areas under the curve (AUC) of the receiver operating
characteristic curves (ROC) were used to compare the power of these serum markers.
Results: In non-obese subjects, the best marker of insulin resistance was alanine aminotransferase (ALT)/aspartate
aminotransferase (AST) ratio of 0.70 (95% confidence interval (CI), 0.63-0.77). In overweight subjects, AUC values for
the ALT/AST ratio and ALT were 0.66 (0.59-0.72) and 0.66 (0.59-0.72), respectively. Multiple linear regression analyses
for HOMA-IR showed that ALT/AST ratios were independently and significantly associated with HOMA-IR as well as
other confounding factors in both non-obese and overweight subjects. The optimal cut-off point to identifying
insulin resistance for these markers yielded the following values: ALT/AST ratio of ≥0.82 in non-obese subjects and
≥1.02 in overweight subjects. In non-obese subjects, the positive likelihood ratio was greatest for ALT/AST ratio.
Conclusions: In non-obese Japanese adults, ALT/AST ratio may be the best reliable marker of insulin resistance.
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Obesity is also a major worldwide public health problem
and is associated with a high risk of developing insulin
resistance [1]. Insulin resistance plays an important role
in the pathogenesis of incident diabetes, hypertension,
dyslipidemia, and cardiovascular disease (CVD) [2-4].
Detailed measurement of insulin resistance requires the
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distribution, and reproduction in any mediumthat require expense and time. Alternatives have been
sought to simplify the measurement of insulin resistance
and one is Homeostatic Model Assessment of insulin
resistance (HOMA-IR), which uses fasting insulin and
glucose levels to calculate insulin resistance [5] and cor-
relates reasonably with the results of clamping studies.
The use of this index is problematic, however, in that in-
sulin levels are not measured during the usual annual
health examination and in clinical practice.
Many studies have demonstrated that alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST) and gamma-
glutamyl transferase (GGT) levels independently predict type
2 diabetes [6-10], metabolic syndrome [11-14], and CVD
[8]. These markers have been shown to be associated withtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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insulin levels [14] and HOMA-IR [10,15-17]. However, in
Japanese community-dwelling persons, there are few studies
to demonstrate a relationship between liver markers and in-
sulin resistance, categorized by BMI. It is important for us to
be able to evaluate insulin resistance by measuring the liver
markers which are inexpensive and routinely measured in
clinical setting.
We took advantage of the large representative sample of
Japanese adults who participated at the time of their annual
health examination. We investigated how liver markers
were associated with insulin resistance in healthy Japanese
adults. For this, we used cross-sectional data from
community-dwelling participants without clinical diabetes.
Methods
Subjects
The present study is designed as a part of the Nomura
study [18]. Subjects were selected through a community-
based annual check-up process in a rural town located
in Ehime prefecture, Japan. A sample of 3,164 subjects
was recruited and the available sample population com-
promised 2,764 subjects. Information on medical history,
present conditions, and drugs was obtained by interview.
Other characteristics, such as smoking and alcohol
habits, and medication, were investigated by individual
interviews using a structured questionnaire. Subjects
taking medications for hypertension (N= 736), diabetes
(N= 153), or dyslipidemia (N = 108) were excluded
(N= 877). For all these individuals, overnight fasting
plasma samples were available for measuring immunor-
eactive insulin (IRI) and high sensitivity C-reactive pro-
tein (hsCRP). We reduced the number of subjects
(N= 545) because the omitted subjects’ samples had a
limited volume of plasma. The final study sample
included 1,342 eligible persons. The final study sample
included 587 men and 755 women. This study was
approved by the ethics committee of Ehime University
School of Medicine, and written informed consent was
obtained from each subject.
Evaluation of confounding factors
Information on demographic characteristics and risk fac-
tors was collected using clinical files. Body mass index was
calculated by dividing weight (in kilograms) by the square
of the height (in meters). Smoking status was defined as
the number of cigarette packs per day multiplied by the
number of years smoked (packyear), and the participants
were classified into never smokers, past smokers, light
smokers (<30 packyear) and heavy smokers (≥30 pack;
year). The daily alcohol consumption was measured using
the Japanese liquor unit in which a unit corresponds to
22.9 g of ethanol, and the participants were classified into
never drinkers, occasional drinkers (<1 unit/day), lightdrinkers (1–1.9 unit/day), and heavy drinkers (≥2 unit/
day). We measured blood pressure in the right upper arm
of the participants in a sedentary position using an auto-
matic oscillometric blood pressure recorder (BP-103i;
Colin, Aichi, Japan) while the subjects were seated after
having rested for at least 5 min. Total cholesterol (T-C),
triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C), fasting plasma glucose (FPG), uric acid, hsCRP,
high molecular weight (HMW) adiponectin (FUJIREBIO,
Tokyo, Japan), GGT, ALT, AST, and IRI were measured
during fasting. Low-density lipoprotein cholesterol (LDL-C)
levels were calculated using the Friedewald formula [19].
Participants with TG levels ≥400 mg/dl were excluded.
HOMA-IR was calculated from FPG and IRI levels using
the following formula; [FPG (mg/dL) X IRI (mU/mL)]/405
[5], and a level of Insulin resistance was defined as
HOMA-IR ≥2.5 [5].
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
Version 20 (Statistical Package for Social Science Japan,
Inc., Tokyo, Japan). All values are expressed as mean±
standard deviation (SD), unless otherwise specified. Data
for TG, hsCRP, serum HMW adiponectin, GGT, ALT, and
AST were skewed, and are presented as median (interquar-
tile range) values, and were log-transformed for analysis.
Subjects were divided into two groups based on BMI [non-
obese, <25.0 kg/m2; overweight, ≥25.0 kg/m2 (waist circum-
ference was not available in this study)], and differences
between the two groups were determined by Student’s t-
test and χ2 test. In addition, areas under the receiver operat-
ing characteristic (ROC) curves were determined for each
variable to identify the predictors of insulin resistance.
Areas under the ROC curves are provided with standard
errors. An ROC curve is a plot of the sensitivity (true posi-
tive) versus 1–specificity (false positive) for each potential
marker tested. The area under the ROC curve is a summary
of the overall diagnostic accuracy of the test. The best mar-
kers have ROC curves that are shifted to the left with areas
under the curve near unity. Nondiagnostic markers are
represented by diagonals with areas under the ROC curves
close to 0.5. Likelihood ratios were calculated as the ratios
of sensitivity/(1-specificity) (positive likelihood ratio) and
(1-sensitivity)/specificity (negative likelihood ratio). Multiple
linear regression analysis was used to evaluate the contribu-
tion of each confounding factor for HOMA-IR. A value of
P <0.05 was considered significant.
Results
Background factors of subjects categorized by BMI
Table 1 shows the value of each background factor
categorized by BMI. The subjects comprised 587 men
aged 58 ± 14 (range, 20–89) years and 755 women
aged 60 ± 12 (range, 21–88) years. The mean BMI in
Table 1 Characteristics of subjects categorized by body mass index
Body mass index† characteristics Total Non-obese Overweight P -value*
All N = 1,342 <25.0 kg/m2 N=998 ≥25.0 kg/m2 N=344
Male sex,% 43.7 42.8 46.5 0.232
Age (years) 59 ± 13 60 ± 13 57 ± 12 0.012
Body mass index (kg/m2) 23.1 ± 3.1 21.7 ± 2.0 27.1 ± 2.2 <0.001
Smoking status {never/ex/light/heavy (%)} 71.2/9.6/9.1/10.1 72.6/8.3/8.9/10.1 66.9/13.4/9.6/10.2 0.043
Alcohol consumption {never/light/moderate/heavy (%)} 38.8/31.8/18.6/10.8 40.5/30.5/18.9/10.1 34.0/35.8/17.4/12.8 0.072
Cardiovascular disease,% 4.5 4.7 4.1 0.764
Systolic blood pressure (mmHg) 134 ± 21 132 ± 21 139± 19 <0.001
Diastolic blood pressure (mmHg) 80 ± 11 79 ± 11 84 ± 10 <0.001
Total cholesterol (mg/dL) 201 ± 35 200 ± 34 205± 35 0.024
Triglycerides (mg/dL) 90 (67–126) 85 (64–117) 108 (81–152) <0.001
HDL cholesterol (mg/dL) 63 ± 15 65 ± 16 57 ± 13 <0.001
LDL cholesterol (mg/dL) 118 ± 32 116 ± 31 123± 32 <0.001
Uric acid (mg/dL) 5.0 ± 1.4 4.8 ± 1.4 5.5 ± 1.4 <0.001
High sensitivity CRP (mg/dL) 0.04 (0.02-0.09) 0.04 (0.02-0.07) 0.07 (0.04-0.15) <0.001
Serum HMW adiponectin (μg/mL) 4.89 (2.98-7.99) 5.37 (3.21-8.69) 3.95 (2.24-5.82) <0.001
GGT (IU/L) 25 (18–43) 22 [17–37] 32 (21–63) <0.001
ALT (IU/L) 17 [13–24] 16 [12–21] 22 [16–31] <0.001
AST (IU/L) 21 [18–26] 21 [18–26] 22 [19–27] 0.013
ALT/AST ratio 0.79 (0.65-1.0) 0.74 (0.63-0.91) 0.96 (0.72-1.2) <0.001
HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP; C-reactive protein; HMW, high molecular weight; GGT, Gamma-glutamyl transferase; ALT, alanine
aminotransferase; AST, aspartate aminotransferase. Data presented are mean ± standard deviation. Data for triglycerides, high sensitivity CRP, serum HMW
adiponectin, GGT, ALT, AST, and ALT/AST ratio were skewed, and are presented as median (interquartile range), and were log-transformed for analysis. * Student’s
t-test or χ2 test.
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(74.4%) non-obese (BMI <25.0 kg/m2) and 344
(25.6%) overweight (BMI ≥25 kg/m2). Prevalence of
smoker, systolic blood pressure (SBP), diastolic blood
pressure (DBP), T-C, TG, LDL-C, uric acid, hsCRP,
GGT, ALT, AST, and ALT/AST ratio were signifi-
cantly higher in subjects with a BMI ≥25.0 kg/m2, but
age, HDL-C and serum HMW adiponectin were sig-
nificantly lower in that group. There were no inter-Table 2 Insulin resistance of subjects categorized by body ma
Body mass index characteristics Total
All N = 1,342 <25
Fasting blood glucose (mg/dL) 92 (87–99)
Immunoreactive insulin (mU/mL) 5.2 (3.4-7.7)
HOMA-IR† 1.20 (0.76-1.84) 1
HOMA-IR† <1.6,% 67.5
HOMA-IR† ≥1.6 and <2.5,% 20.0
HOMA-IR† ≥2.5,% 12.4
HOMA-IR, homeostasis of minimal assessment of insulin resistance. Data for fasting
and are presented as median (interquartile range). †HOMA-IR was calculated using
Immunoreactive insulin (mU/mL)]/405. Data for fasting blood glucose, Immunoreac
χ2 test.group differences in sex, alcohol consumption, and
prevalence of CVD.Insulin resistance of subjects categorized by BMI
FBG, IRI, and HOMA-IR were significantly higher in over-
weight subjects (Table 2), and prevalence of insulin resist-
ance (HOMA-IR ≥1.6 or ≥2.5) was significantly higher in
overweight subjects than in non-obese subjects.ss index
Non-obese Overweight P -value*
.0 kg/m2 N=998 ≥25.0 kg/m2 N=344
91 (86–98) 96 (89–103) <0.001
4.5 (3.0-6.6) 8.0 (5.4-11.2) <0.001




blood glucose, fasting immunoreactive insulin, and HOMA-IR were skewed,
the following formula; [fasting blood glucose (FBG) (mg/dL) X fasting
tive insulin, and HOMA-IR were log-transformed for analysis. *Student’s t test or
Table 3 Comparison of areas under the ROC curves (95% CI) for potential markers of insulin resistance (HOMA-IR ≥2.5)
of subjects categorized by body mass index
Body mass index characteristics AUC (95% CI)
Total P-value Non-obese P-value Overweight P-value
All N= 1,342 <25.0 kg/m2 N=998 ≥25.0 kg/m2 N=344
Triglycerides (mg/dL) 0.69 (0.65-0.73) <0.001 0.66 (0.59-0.73) <0.001 0.65 (0.58-0.71) <0.001
High sensitivity CRP (mg/dL) 0.68 (0.64-0.72) <0.001 0.61 (0.55-0.68) 0.003 0.63 (0.57-0.70) <0.001
Serum HMW adiponectin (μg/mL) 0.32 (0.28-0.36) <0.001 0.32 (0.25-0.39) <0.001 0.40 (0.33-0.46) 0.003
GGT (IU/L) 0.63 (0.58-0.67) <0.001 0.61 (0.54-0.67) 0.005 0.54 (0.48-0.61) 0.211
ALT (IU/L) 0.69 (0.64-0.73) <0.001 0.62 (0.55-0.69) 0.002 0.66 (0.59-0.72) <0.001
AST (IU/L) 0.56 (0.51-0.61) 0.013 0.49 (0.41-0.57) 0.818 0.59 (0.52-0.66) 0.007
ALT/AST ratio 0.74 (0.70-0.78) <0.001 0.70 (0.63-0.77) <0.001 0.66 (0.59-0.72) <0.001
ROC, receiver operating characteristics; CI, confidence interval; AUC, area under ROC curve. Data for triglycerides, high sensitivity CRP, serum HMW adiponectin,
GGT, ALT, AST, and ALT/AST ratio were skewed and log-transformed for analysis.
Kawamoto et al. Cardiovascular Diabetology 2012, 11:117 Page 4 of 8
http://www.cardiab.com/content/11/1/117Comparison of areas under ROC curves [95% confidence
interval] for potential markers of insulin resistance of
subjects categorized by BMI
In non-obese subjects, the ROC curve analyses showed that
the best marker of insulin resistance was ALT/AST ratio,
with an area under the ROC curve of 0.70 (0.63-0.77)
(Table 3; Figure 1). Serum HMW adiponectin, ALT, and
hsCRP also discriminated insulin resistance, as they had
areas under the ROC curve of 0.32 (0.25-0.39), 0.62 (0.55-
0.69), and 0.61 (0.55-0.68), respectively. In overweight sub-
jects, ALT/AST ratio and ALT were more effective.
Relationship between various confounding factors and
HOMA-I of subjects categorized by body mass index
Figure 2 shows the relationships between AST/ALT ratio
and HOMA-IR. AST/ALT ratio was also significantly
associated with measures of HOMA-IR in both non-obese
(r = 0.274, P< 0.001) and overweight subjects (r = 0.253,Figure 1 Receiver operating characteristics (ROC) curves. Sensitivity rep
results. The best markers have ROC curves that are shifted to the left with a
represented by diagonals with areas under the ROC curves close to 0.5.P<0.001). To further investigate whether AST/ALT ratio
can explain the changes in HOMA-IR levels independent
of other known confounding factors, multiple linear re-
gression analyses for HOMA-IR showed that AST/ALT
ratio was independently and significantly associated with
HOMA-IR in both non-obese (β=0.129, P< 0.001) and
overweight subjects (β=0.143, P=0.038) (Table 4).Optimal cut-off point of ALT/AST ratio for predicting
insulin resistance of subjects categorized by BMI
Table 5 shows the cut-off points of ALT/AST ratio for
identifying insulin resistance. The optimal cut-off point
to identifying insulin resistance for these markers yielded
the following values: ALT/AST ratio of ≥0.82 in non-
obese subjects, and ≥1.02 in overweight. In non-obese
subjects, the positive likelihood ratio value indicates that
the odds of insulin resistance increased by 1.91-fold ifresents the true-positive results and 1-specificity, the false-positive
reas under the curve near unity. Nondiagnostic markers are
Figure 2 Correlation between AST/ALT ratio and HOMA-IR
categorized by BMI. Data for HOMA-IR were skewed and
log-transformed for analysis. The lines of best fit (BMI <25.0 kg/m2:
r = 0.274, P< 0.001; BMI ≥25.0 kg/m2: r = 0.253, P< 0.001) are
indicated.
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tive likelihood ratios indicate the extent to which the
odds of insulin resistance decrease if the test is negative.
These odds also decreased more so for ALT/AST ratio.
In overweight subjects, these values were similar.Table 4 Multiple linear regression analysis of the correlation
subjects categorized by body mass index
Body mass index† characteristics
Tota
All N = 1
Male sex,% 0.247 (<0
Age (years) −0.064 (0
Body mass index (kg/m2) 0.320 (<0
Smoking status {never/ex/light/heavy (%)} −0.065 (0
Alcohol consumption {never/light/moderate/heavy(%)} −0.114 (<0
Cardiovascular disease,% 0.032 (0.1
Systolic blood pressure (mmHg) 0.093 (<0
Triglycerides (mg/dL) 0.138 (<0
HDL cholesterol (mg/dL) −0.033 (0
LDL cholesterol (mg/dL) 0.041 (0.0
Uric acid (mg/dL) 0.021 (0.4
High sensitivity CRP (mg/dL) 0.049 (0.0
Serum HMW adiponectin (μg/mL) −0.164 (<0
GGT (IU/L) 0.097 (0.0
ALT/AST ratio 0.122 (<0
R2 0.417 (<0
Data for triglycerides, high sensitivity CRP, serum HMW adiponectin, GGT, ALT/ASTRelationship between ALT/AST ratio and insulin resistance
of subjects within selected subgroups
Next, to control potential confounding by gender and
BMI, the data were further stratified by gender and BMI
(Table 6). In both genders with a BMI of 22.0 to 25.0 kg/m2,
AST/ALT ratio was a reliable marker of insulin re-
sistance, but in subjects with a BMI of <22.0 kg/m2,
AST/ALT ratio was not significantly associated with
HOMA-IR.
Discussion
In the present study, we examined whether liver markers
(e.g., GGT, ALT, AST, and ALT/AST ratio) as well as
gender, age, BMI, smoking status, alcohol consumption,
SBP, lipid profiles, uric acid, and serum HMW adiponec-
tin were associated with insulin resistance in Japanese
adults, categorized by body mass index. Most fundamen-
tal is the fact that not all overweight or obese persons
are insulin resistant. In non-obese subjects, 6.2% of them
were insulin resistant, and the best marker of insulin
resistance was ALT/AST ratio, but serum HMW adipo-
nectin, ALT, and hsCRP also discriminated insulin resist-
ance. In the overweight subjects, areas of the ALT/AST
ratio and ALT were greater than those of the other para-
meters. The optimal cut-off point to identifying
insulin resistance for these markers yielded the follow-
ing values: ALT/AST ratio of ≥0.82 in the non-obese,
and ≥1.02 in the overweight subjects. The positivebetween various confounding factors and HOMA-IR of
β(P -value)
l Non-obese Overweight
,342 <25.0 kg/m2 N=998 ≥25.0 kg/m2 N=344
.001) 0.281 (<0.001) 0.219 (0.005)
.020) −0.116 (0.001) 0.094 (0.135)
.001) 0.206 (<0.001) 0.262 (<0.001)
.014) −0.060 (0.075) −0.103 (0.073)
.001) −0.137 (<0.001) −0.081 (0.222)
40) 0.055 (0.046) −0.024 (0.610)
.001) 0.126 (<0.001) 0.032 (0.543)
.001) 0.145 (<0.001) 0.164 (0.005)
.215) −0.038 (0.249) −0.028 (0.645)
79) 0.063 (0.034) 0.010 (0.848)
51) 0.049 (0.153) −0.052 (0.400)
35) 0.048 (0.095) 0.074 (0.149)
.001) −0.162 (<0.001) −0.231 (0.001)
01) 0.079 (0.031) 0.149 (0.038)
.001) 0.129 (<0.001) 0.143 (0.038)
.001) 0.315 (<0.001) 0.290 (<0.001)
ratio and HOMA-IR were skewed and log-transformed for analysis.
Table 5 Comparison of ALT/AST ratio for predicting of insulin resistance (HOMA-IR ≥2.5) of subjects categorized by
body mass index
Characteristics cut-off point HOMA-IR}
<2.5 ≥2.5 Sensitivity Specificity Positive LR Negative LR Accuracy
Body mass index <25.0 kg/m2 N= 936 N= 62 %
ALT/AST ratio <0.82 612 22 0.67 0.65 1.91 0.51 65.3
ALT/AST ratio ≥0.82 324 40
Body mass index ≥25.0 kg/m2 N= 239 N= 105
ALT/AST ratio <1.02 158 41 0.66 0.61 1.69 0.56 64.5
ALT/AST ratio ≥1.02 81 64
LR, likelihood ratio.
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non-obese subjects. ALT/AST ratio, an inexpensive and
routinely measured clinical variable, might be used as an
integrated parameter and measure to evaluate insulin
resistance in community-dwelling persons, especially
non-obese subjects.
Insulin resistance is common and when clustered with
glucose intolerance, dyslipidemia and high blood pressure,
and present in type 2 diabetes it play a key role in the oc-
currence of hyperglycemia. Resistance to insulin-mediated
glucose disposal is distributed continuously through the
general population [20], and we have no criterion with
which to identify a participant as being insulin resistance.
However, we classified a participant with a HOMA-IR of
>2.5 as insulin resistance [21]. Some previous studies have
demonstrated that HOMA-IR strongly correlates with glu-
cose clamp–assessed insulin resistance [5,20] and has the
advantage of requiring only a single plasma sample
assayed for insulin and glucose. However, HOMA-IR is
less accurate and precise than the glucose clamp methodTable 6 Association between ALT/AST ratio and insulin resista
subgroups
Stratified subgroups N HOMA-IR ≥2.5,%
Men Body mass index (kg/m2)
Total 587 66 (11.2)
<22.0 202 7 (3.5)
22.0-25.0 225 19 (8.4)
<25.0 427 26 (6.1)
≥25.0 160 40 (25.0)
Women Body mass index (kg/m2)
Total 755 101 (13.4)
<22.0 308 10 (3.2)
22.0-25.0 263 26 (9.9)
<25.0 571 36 (6.3)
≥25.0 184 65 (35.3)
Multivariate-adjusted for confounding factors in Table 4.in measuring insulin resistance, but this limitation is now
mitigated, because the HOMA model has become a
widely used clinical and epidemiological tool, as in our
study [22,23]. Thus, we used HOMA-IR as a marker of in-
sulin resistance in this study.
In previous studies, several lipid ratios have been pro-
posed as simple and useful clinical indicators of insulin
resistance. The TG/HDL-C, the T-C/HDL-C, and the
LDL-C/HDL-C ratio have shown similar potential for in-
sulin resistance, though the reports are not entirely con-
sistent [24-27]. Also in our study, both LDL-C/HDL-C
and TG/HDL-C ratio were useful markers of insulin re-
sistance, especially in all subjects or non-obese subjects.
However, these markers were weaker in overweight sub-
jects [28]. ALT/AST ratio as well as LDL-C/HDL-C and
the TG/HDL-C ratio were also strongly related to insulin
resistance. Several studies have reported a significant as-
sociation of ALT with HOMA-IR [15,29,30]. Moreover,
Hanley et al. [30,31] reported that ALT/AST ratio pre-








0.75 (0.68-0.81 0.253 (<0.001) 0.104 (0.016)
0.67 (0.44-0.89) 0.257 (<0.001) 0.141 (0.051)
0.64 (0.51-0.77) 0.317 (<0.001) 0.166 (0.030)
0.67 (0.56-0.77) 0.274 (<0.001) 0.143 (0.004)
0.73 (0.63-0.82) 0.215 (0.005) 0.052 (0.600)
0.75 (0.70-0.81) 0.197 (<0.001) 0.104 (0.002)
0.74 (0.62-0.87) 0.149 (0.008) 0.055 (0.334)
0.71 (0.60-0.82) 0.250 (<0.001) 0.136 (0.039)
0.74 (0.65-0.82) 0.194 (<0.001) 0.092 (0.026)
0.68 (0.60-0.76) 0.231 (0.001) 0.176 (0.019)
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lin sensitivity and acute insulin response. ALT/AST ratio
that includes information on at least two measures
might have a more integrated explanation than single
measures such as ALT or TG.
There are a number of possible mechanisms that can
explain the association between the ALT/AST ratio and
insulin resistance. Fat accumulation in the liver is charac-
terized by several features of insulin resistance in normal
weight and moderately overweight subjects, independent
of BMI and intra-abdominal and overall obesity [32].
Increased liver fat content, a disorder that has detrimental
effects on components of the metabolic syndrome, is
known to be significantly correlated with these markers
[33]. Nanji et al. [34] reported a significant correlation be-
tween ALT/AST ratio and the degree of fatty infiltration
of the liver. Moreover, non-alcoholic fatty liver disease
(NAFLD), which has recently been proposed as a feature
of the metabolic syndrome [35], was also characterized by
chronic elevations in liver transaminase levels, including
ALT, AST, and GGT [36,37]. ALT/AST ratio and ALT per
se along with the cut-off points might be reflecting
NAFLD, but in this study, we have not evaluated ultra-
sound liver findings. Although, this study is of interest be-
cause liver transaminase markers, which are inexpensive
and routinely collected in clinical settings, may provide a
simple and accurate enhancement to models currently
used to identify subjects with insulin resistance.
Some limitations of this study must be considered. First,
the cross-sectional study design is limited in its ability to
eliminate causal relationships between ALT/AST ratio and
HOMA-IR. Second, our definition of HOMA-IR is based on
a single assessment of FBS and IRI, which may introduce
misclassification bias, although common to most epidemio-
logical studies. However, random errors due to the fluctua-
tions of laboratory measurements usually lead to a reduced
estimate of the associated strength. Third, our study parti-
cipants might include patients with subclinical liver diseases
(i.e., chronic viral hepatitis, or drug–induced liver injury).
These liver diseases are present in community-dwelling per-
sons and are usually asymptomatic. Therefore the demo-
graphics and referral source may limit generalizability.
Conclusions
The present study demonstrated that ALT/AST ratio is
associated with insulin resistance according to BMI in a
general population. The ability to identify who is non-obese
or overweight and who is insulin resistant could help health
care professionals in bringing about lifestyle interventions.
In that context, use of the cutoff-points of ALT/AST ratio
described in this report is simple and useful. The present
data documented that in non-obese Japanese adults
ALT/AST ratio may be the best reliable marker of insulin
resistance. Further prospective population-based studies areneeded to investigate the changes in lipid metabolism by
lifestyle interventions.
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